All
FDA Assigns Priority Review to Lenvatinib Plus Everolimus Combo in RCC
January 19th 2016The combination of lenvatinib (Lenvima) and everolimus (Afinitor) has been given a priority review status by the FDA as a treatment for patients with metastatic renal cell carcinoma (RCC) following one prior VEGF-targeted therapy.
FDA Approves Ofatumumab for Elongated Treatment of Patients With CLL
January 19th 2016Ofatumumab (Arzerra) has received FDA approved for the extended treatment of patients with recurrent or progressive chronic lymphocytic leukemia (CLL). Patients eligible to receive the treatment must show complete or partial response following at least two lines of therapy.
Post-Study Paradigm Shift in CML Highlights Need for Accurate Molecular Monitoring
January 14th 2016A new retrospective study claimed a rarity of cytogenetic and molecular monitoring exists among patients with chronic myelogenous leukemia (CML) treated in a community setting; however, one researcher is challenging that claim.
FDA Issues Venetoclax Priority Review as Second-Line Treatment in CLL
January 12th 2016Venetoclax has been granted priority review status by the FDA for use in adults with chronic lymphocytic leukemia (CLL) following at least 1 prior therapy. This patient population includes those with a 17p deletion (del[17p]), according to codevelopers of the BCL-2 inhibitor AbbVie and Genentech.
DNA Repair Defects Vital to PARP Inhibitor's Strength in Prostate Cancer
January 9th 2016A current estimation shows that roughly 25% of metastatic castration-resistant prostate cancers (mCRPC) contain alterations in DNA repair genes. These would normally code for proteins to correct errors arising when cells duplicate their DNA before cell division.
Gene Suppressing Some Cancer Types Could Be Lethal in Colorectal Cancer
January 5th 2016A gene associated with the suppression of tumor growth has been found to act in the opposite manner in some forms of colorectal cancer (CRC), according to researchers at the University of Missouri School of Medicine.
CT-Planned, High-Dose-Rate Brachytherapy Shows Local Control, Survival Benefit in Cervical Cancer
January 2nd 2016The use of computed-tomography (CT)-planned high-dose-rate (HDR) intracavitary brachytherapy (BT) demonstrated excellent local control (LC) and survival for patients with stage I/II cervical carcinoma.
Checkpoint Inhibitors Could Be the Backbone of Therapy in Advanced Renal Cell Carcinoma
December 30th 2015The programmed cell death 1 (PD-1) and PD-1 ligand (PD-L1) inhibitors "are going to disrupt the current treatment paradigm and will likely be the backbone of combination therapy," said Hans J. Hammers, MD, PhD.
New Study Seeks to Assess Tolerability of Emerging Nivolumab Combination
December 29th 2015An upcoming phase I trial seeks to evaluate a combination of interferon gamma-1b (ACTIMMUNE) and nivolumab (Opdivo) in patients with advanced solid tumors who have progressed on at least one prior systemic therapy.
FDA Approves Non-Alcohol Formulation of Docetaxel for Multiple Cancer Types
December 29th 2015The FDA has approved a new treatment consisting of a non-alcohol formulation of docetaxel in patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.